Author: admin

Blood Pressure Cuffs Market worth $1,399 million by 2029

“Prominent players in the market include Omron Corporation, Inc. (Japan), Baxter International Inc. (US), Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), and McKesson Corporation. (US), B Braun Melsungen AG (Germany), Halma plc (Uk), OSI Systems, Inc. (US), American Diagnostic Corporation (US)”
Browse 268 market data Tables and 49 Figures spread through 270 Pages and in-depth TOC on “Blood Pressure Cuffs Market by Type (Automated, Manual), Size (8-19 cm, 19 cm & Above), Usage (Reusable, Disposable), Age Group (Infants & children, Adults), Distribution Channel (Online, Offline), End User (Hospitals, Clinics) – Global Forecast to 2029

The global blood pressure cuffs market is projected to grow from USD 909 million in 2024 to USD 1,399 million by 2029, at a CAGR of 9.0%, driven by factors like the rising elderly population, increasing prevalence of hypertension, and the growth of telehealth and remote patient monitoring. Key market dynamics include a rising incidence of cardiovascular diseases and hypertension, and the need for reliable blood pressure monitoring tools. However, challenges such as the risk of healthcare-associated infections from reusable cuffs and issues with cuff sizing may impact market dynamics. Opportunities are emerging from advancements in remote monitoring technologies, such as Healthmote’s IoT-connected cuffs, which enhance patient care. The market is segmented into automated versus manual cuffs, reusable versus disposable, and various cuff sizes. The largest share is held by automated, reusable cuffs and the adult age group, with North America leading the market, followed by Asia Pacific due to its growing healthcare infrastructure and high prevalence of cardiovascular conditions. Major players in the market include Omron Corporation, Baxter International, McKesson Corporation, and Koninklijke Philips N.V.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14931460

Competitive Landscape and Major Players

The blood pressure cuffs market is competitive, with OMRON Corporation (Japan), Baxter International Inc. (US), and McKesson Corporation (US) being the leading players. These companies employ a mix of organic and inorganic growth strategies, including expansions, agreements, and acquisitions, to enhance their product offerings, meet customer needs, boost profitability, and solidify their market presence.

OMRON Corporation (Japan)

Omron Corporation is a prominent player in the global market, offering a diverse range of products across multiple industries. Its healthcare division, Omron Healthcare Co., Ltd., specializes in cardiovascular, respiratory, and home healthcare products, including blood pressure monitors. Omron forecasts sales to reach USD 0.91 billion (about 146.0 billion yen) through the expansion of online channels and increased demand in emerging markets, indicating significant growth potential in the blood pressure cuffs market.

Baxter International Inc. (US)

Baxter International Inc. provides a broad spectrum of critical healthcare products, including patient care and diagnostic technologies. Its Healthcare Systems and Technologies segment, which encompasses connected care solutions and patient monitoring systems, is vital to Baxter’s strategy. The acquisition of Hill-Rom Holdings, Inc. for USD 10.48 billion in December 2021 aimed to enhance Baxter’s market position and expand its portfolio, including its offerings in blood pressure monitors.

McKesson Corporation (US)

McKesson Corporation, through its various affiliates, is a leading global provider of healthcare services designed to improve patient outcomes. The company’s Medical-Surgical Solutions segment supplies blood pressure cuffs, distribution, logistics, and additional services to healthcare providers such as doctor’s offices, surgery centers, and home healthcare agencies. McKesson partners with manufacturers and channel partners to support government, extended care, and primary care markets effectively.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14931460

Understanding Blood Pressure Measurement

A sphygmomanometer, or blood pressure cuff, is used by doctors to measure blood pressure. The cuff is inflated around the upper arm to block blood flow, and as it deflates, a stethoscope is used to listen to the blood flow, with the cuff’s gauge recording these sounds. This method allows for accurate assessment of heart health and overall well-being across various settings such as clinics, hospitals, and home care.

Market Segmentation by Type

The blood pressure cuff market is categorized into automated and manual types. In 2023, automated blood pressure cuffs held the largest market share due to the growing adoption of advanced monitoring technology, which offers ease of use and precision.

Market Segmentation by Size

The market is divided into two size categories: 8-19 cm and 19 cm & above. The segment for cuffs sized 19 cm and above led the market in 2023. This dominance is due to the high prevalence of hypertension and cardiovascular issues among adults, which necessitates regular and precise blood pressure monitoring.

Reusable vs. Disposable Cuffs

In 2023, reusable blood pressure cuffs dominated the market. Their cost-effectiveness and durability make them particularly suitable for large hospitals and clinical environments, where the benefits of reusability outweigh the initial costs.

Market Segmentation by Age Group

The market is divided into adults and infants & children. The adult segment represented the largest share in 2023. This is largely due to the growing elderly population, who are more susceptible to hypertension and related chronic conditions like diabetes and kidney disease.

Distribution Channels

The blood pressure cuffs market is segmented into offline and online distribution channels. In 2023, offline channels held the largest market share. This is due to their wide accessibility and convenience for distribution across hospitals, clinics, and home care settings.

End Users

The market is divided into hospitals, clinics, homecare, and other end users. Hospitals were the major players in 2023, benefiting from the increasing number of elderly patients needing regular monitoring. Technological advancements, such as wireless cuffs, are expected to further boost hospital growth in the blood pressure cuffs market.

Regional Market Insights

The global blood pressure cuffs market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. North America led the market in 2023, followed by Asia Pacific and Europe. The region’s dominant position is attributed to the presence of major market players, an aging population, and a high prevalence of hypertension and cardiovascular diseases.

For more information, inquire now! Inquire Now

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/blood-pressure-cuffs-market-14931460.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blood Pressure Cuffs Market worth $1,399 million by 2029

Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Neuroendocrine tumors Pipeline Insight, 2024” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook

 

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

  • In October 2024:- Novartis Pharmaceuticals- This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
  • In October 2024:- Iovance Biotherapeutics Inc.- This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
  • DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Neuroendocrine Tumors treatment.
  • The leading Neuroendocrine Tumors Companies such as RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, and others.
  • Promising Neuroendocrine Tumors Therapies such as Lutetium[177Lu] Oxodotreotide Injection, Everolimus, CAM2029, Octreotide LAR, Lanreotide ATG, and others.

 

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

 

Neuroendocrine Tumors Emerging Drugs Profile

  • RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently, the drug is in the Phase III stage of development to treat Neuroendocrine tumors.

  • SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells (“SVV-permissive cells”), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

 

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight’s detailed report now! @ New Neuroendocrine Tumors Drugs

 

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

 

Scope of the Neuroendocrine Tumors Pipeline Report

  • Coverage- Global
  • Neuroendocrine Tumors Companies- RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, and others.
  • Neuroendocrine Tumors Therapies- Lutetium[177Lu] Oxodotreotide Injection, Everolimus, CAM2029, Octreotide LAR, Lanreotide ATG, and others.
  • Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Neuroendocrine Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RYZ101: RayzeBio, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SVV-001: Seneca Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DD01: D&D Pharmatech
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Neuroendocrine Tumors Key Companies
  21. Neuroendocrine Tumors Key Products
  22. Neuroendocrine Tumors- Unmet Needs
  23. Neuroendocrine Tumors- Market Drivers and Barriers
  24. Neuroendocrine Tumors- Future Perspectives and Conclusion
  25. Neuroendocrine Tumors Analyst Views
  26. Neuroendocrine Tumors Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Guidewires Market 2024-2032: Global Industry Analysis, Share, Size, Growth and Forecast

The global guidewires market size reached USD 1.1 Million in 2023. Looking forward, IMARC Group expects the market to reach USD 1.5 Million by 2032, exhibiting a growth rate (CAGR) of 3.71% during 2024-2032.

Guidewires Industry

Summary:

  • The global guidewires market size reached USD 1.1 Billion in 2023.
  • The market is expected to reach USD 1.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.71% during 2024-2032.
  • North America leads the market, accounting for the largest guidewires market share.
  • Surgical guidewires account for the majority of the market share in the product segment as they offer enhanced precision and control, enabling surgeons to navigate complex anatomical pathways with minimal risk of damage.
  • Nitinol holds the largest share in the guidewires industry.
  • Coronary represents the leading application segment.
  • Based on the end user, the market has been segmented into hospitals, diagnostic centers and surgical centers, ambulatory care centers (ACC), and others.
  • The increasing prevalence of cardiovascular conditions worldwide is a primary driver of the guidewires market.
  • Innovations in guidewire design and the development of advanced coatings are reshaping the guidewires market.

Request Sample For PDF Report: https://www.imarcgroup.com/guidewires-market/requestsample

Industry Trends and Drivers:

  • Rising incidence of cardiovascular diseases:

The guidewires market is primarily driven by the rising prevalence of cardiovascular diseases (CVDs), such as coronary artery disease, peripheral artery disease, and stroke. With sedentary lifestyles, poor dietary habits, and rising rates of obesity and diabetes, cardiovascular issues have become a leading cause of death worldwide. This rise in CVD cases has significantly increased the demand for minimally invasive diagnostic and therapeutic procedures, where guidewires play a vital role. Guidewires are essential tools in numerous cardiovascular interventions, such as angioplasty, stenting, and catheterization, as they help navigate complex arterial systems with precision. As the global burden of cardiovascular diseases continues to grow, the demand for guidewires in interventional cardiology is steadily rising.

  • Technological advancements in guidewires:

Technological advancements in guidewire design and functionality are contributing substantially to the growth of the guidewires market. Modern guidewires are being developed with enhanced flexibility, durability, and improved tip design, allowing for better maneuverability and control during complex procedures. These advancements reduce the risk of complications, such as arterial perforation or vessel damage, and improve overall procedural outcomes. Additionally, the development of hydrophilic and hydrophobic coatings on guidewires has significantly enhanced their performance by reducing friction, making it easier for surgeons to navigate through vascular pathways. As technology continues to evolve, guidewires are becoming more sophisticated and reliable, leading to their widespread adoption in complex medical procedures and facilitating overall industry expansion.

  • Growing geriatric population and demand for minimally invasive procedures:

The increasing geriatric population is significantly influencing the guidewires market, as elderly individuals are more prone to chronic conditions, including cardiovascular diseases, peripheral vascular diseases, and neurological disorders. Due to this, there is a rising demand for minimally invasive procedures that offer quicker recovery times, fewer complications, and less postoperative pain compared to traditional surgeries. Guidewires are crucial in minimally invasive surgeries, where they are used to guide catheters and other devices through the vascular system with minimal disruption to the surrounding tissues. This preference for minimally invasive techniques among elderly patients, due to their lower risk and shorter hospital stays, is propelling the demand for guidewires across various medical specialties and creating a favorable market outlook overall.

Guidewires Market Report Segmentation:

Breakup By Product:

  • Surgical Guidewires 
    • Hydrophilic Surgical Guidewires
    • Hydrophobic Surgical Guidewires
  • Diagnostic Guidewires
    • Hydrophilic Diagnostic Guidewires
    • Hydrophobic Diagnostic Guidewires

Surgical guidewires account for the majority of shares due to their vital role in minimally invasive procedures, particularly in cardiovascular, neurovascular, and peripheral vascular surgeries.

Breakup By Material:

  • Nitinol
  • Stainless Steel
  • Others

Nitinol dominates the market due to its superior flexibility, shape memory, and kink resistance.

Breakup By Application:

  • Coronary
  • Neurovascular
  • Urology
  • Others

Coronary exhibits a clear dominance due to the high prevalence of cardiovascular diseases, driving demand for precision tools in coronary interventions such as angioplasty and stenting.

Breakup By End User:

  • Hospitals, Diagnostic Centers and Surgical Centers
  • Ambulatory Care Centers (ACC)
  • Others

Based on the end user, the market has been segregated into hospitals, diagnostic centers and surgical centers, ambulatory care centers (ACC), and others.

Buy Report: https://www.imarcgroup.com/checkout?id=2323&method=502

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Top Guidewires Market Leaders: 

  • Abbott Laboratories
  • AngioDynamics Inc.
  • ASAHI INTECC Co., Ltd.
  • B. Braun (B. Braun Holding GmbH & Co. KG)
  • Boston Scientific
  • C. R. Bard Inc. (Becton, Dickinson and Company)
  • Cardinal Health
  • Cook Medical Incorporated (Cook Group)
  • Johnson & Johnson
  • Medtronic Plc
  • Merit Medical Systems Inc.
  • Olympus Corporation
  • Stryker Corporation
  • Teleflex Medical Inc.
  • Terumo Corporation

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse More Related Reports:

About Us:IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. 

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1-631-791-1145
Address:134 N 4th St.
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Guidewires Market 2024-2032: Global Industry Analysis, Share, Size, Growth and Forecast

Health Ingredients Market Overview, Size, Share, Growth Drivers, Trends, Opportunities, Key Segments, Leading Players, and Revenue Fotecast – 2027

“MarketsandMarkets™”
Health Ingredients Market by Type (Vitamins, Minerals, Probiotics starter culture, Prebiotics, Nutritional Lipids, Functional Carbohydrates, Plant and Fruit Extracts, Enzymes, Proteins), Application, Source, Function and Region – Global Forecast to 2027

The health ingredients market size is expected to expand at a CAGR of 7.8% from 2022 to 2027, growing from $100.5 billion in 2022 to $146.3 billion by 2027. This growth is driven by trends in personalized nutrition and nutrigenomics within the food industry, enabling the production of need-specific products. These products serve functional purposes, including supporting the immune system, aiding digestion, promoting mental health, enhancing beauty, and improving cardiovascular health, among other benefits.

Health Ingredients Market

Health Ingredients Market Trends

Here are some key trends in the health ingredients market:

Rise of Plant-Based Ingredients: Increasing consumer demand for plant-based products is driving the popularity of health ingredients derived from plants, such as plant proteins, fibers, and extracts.

Functional Foods: There’s a growing interest in foods that offer health benefits beyond basic nutrition, such as probiotics, prebiotics, omega-3 fatty acids, and antioxidants.

Personalized Nutrition: Tailored dietary solutions based on individual health needs and genetic profiles are gaining traction, leading to increased demand for specific health ingredients.

Clean Label Movement: Consumers are increasingly looking for transparency in ingredient sourcing and processing, prompting brands to use simpler, recognizable ingredients without artificial additives.

Sustainable Sourcing: Sustainability is a significant concern, with a preference for ethically sourced, organic, and non-GMO ingredients driving market dynamics.

Emerging Nutraceuticals: Ingredients like adaptogens, nootropics, and functional mushrooms are becoming popular for their perceived health benefits, including stress reduction and cognitive enhancement.

Health Ingredients Market Opportunities: Shift towards plant-based health ingredients

The plant protein ingredients market is experiencing significant growth as consumers increasingly move away from animal proteins in favor of plant-based alternatives. This trend is likely to propel interest in plant-based herbal supplements and botanicals, further boosting opportunities within the herbal supplements sector. Consumers’ preference for plant extracts is driven by a demand for clean-label products, sustainability concerns, and a need to avoid allergens. The audience for herbal supplements is broadening from vegans to flexitarians, reflecting changing consumer preferences and creating new opportunities in the health ingredients market.

Plant-Based Foods: The Leading Source Projected to Dominate the Health Ingredients Market Share Throughout the Forecast Period.

Plant-based diets are gaining popularity due to several factors, including the rise of vegan culture, heightened health awareness, and growing concerns about animal welfare. These trends have spurred the growth of the plant-based food ingredient market. According to a 2021 report by the Good Food Institute, plant-based foods have outpaced total food sales in both dollar and unit growth over the past three years. Specifically, sales of plant-based foods surged by 54%, while total food sales only grew by 2%. Additionally, unit sales of plant-based foods rose by 6% during this period, in contrast to stagnant total food unit sales, highlighting the significant role of plant-based foods in driving retail growth within the health ingredients market.

Which application within the Food segment is projected to lead in health ingredients market share?

Health ingredients are additives incorporated into food products during manufacturing to enhance their nutritional value and support consumer well-being. These ingredients can be tailored to meet the specific nutritional needs of various consumers, especially those who exercise regularly and require different levels of proteins, carbohydrates, and vitamins. As demand rises for tasty, convenient, and healthy options, bakery product manufacturers are increasingly exploring diverse ingredients. For example, in the Asia Pacific region, George Western Foods (Australia), a subsidiary of Associated British Foods (UK), prominently uses omega-3 fatty acids in its bakery items under the Tip Top brand.

The APAC Region is Anticipated to Hold the Dominant Health Ingredients Market Share During the Forecast Period.

The Asia-Pacific region stands out as one of the largest markets for health ingredients globally, primarily due to rapid urbanization, which has led to widespread vitamin and mineral deficiencies among the population. This situation presents significant opportunities for major manufacturers of dietary supplements and functional foods and beverages to expand their presence and solidify their status as regional market leaders. The region has seen a rising incidence of chronic diseases, including diabetes, cardiovascular conditions, osteoporosis, and arthritis.

According to data from India in 2020, obesity rates surged by 20%, while cardiovascular diseases (CVDs) account for 40% of the nation’s fatalities. Projections indicate that India could become the diabetes capital of the world by 2030, with an estimated 67 million individuals living with diabetes and another 30 million at pre-diabetic stages. These trends are expected to significantly boost the demand for health ingredient products in India. Key industry players, such as Amway, Dabur, Novartis, and Aventis Pharma, are committed to offering a diverse range of products to meet the growing consumer demand for dietary supplements.

Top Health Ingredients Companies:

The key players in this market include Archer Daniels Midland Company (ADM) (US), Associated British Foods PLC (UK), International Flavors & Fragrances Inc. (US), Kerry Group PLC (Ireland), DSM (Netherlands), BASF SE (Germany), Cargill Incorporated (US), Ingredion (US), Arla Foods (Denmark), Tate & Lyle (UK), Lonza (Switzerland), Royal FrieslandCampina N.V. (Netherlands), Glanbia PLC (Ireland), CHR Hansen Holdings A/S, (Denmark), and Probi (Sweden).

Associated British Foods PLC is a highly diversified group with a wide range of food and ingredient businesses and a flagship retail brand, Primark. The company has been in the food and ingredient business for eight decades and operates in 53 countries across Europe, South Africa, North America, South America, Asia, and Australia. It has five business segments: sugar, agriculture, retail, grocery, and ingredients. The company offers health ingredients through the ingredients segment.

The ingredients segment is further classified into two specialty ingredients businesses—AB Mauri (UK) and ABF Ingredients (UK).

1. ABF Ingredients manufactures specialty ingredients and value-added products for the food, nutrition, pharmaceutical, and feed industries. It comprises six groups of ingredients companies: AB Enzymes (Germany), ABITEC (US), Fytexia Group (France), Ohly (Germany), PGP International (US), and SPI Pharma (US).

2. AB Mauri is a yeast and bakery ingredients business with significant market positions in the Americas, Europe, and Asia. It supplies bakery ingredients, bread improvers, dough conditioners, and bakery mixes to industries across the globe. It has over 52 plants, operations in 32 countries, and sales in over 100 countries

International Flavors & Fragrances Inc. is an industry leader in food, beverage, health, biosciences, and sensorial solutions. The company has four business segments: Nourish, Health & Bioscience, Scent, and Pharma Solutions. IFF Health & Bioscience was formerly DuPont Nutrition & Bioscience, which the company merged in 2021. It offers health ingredients through its health & bioscience business segment. The company has over 110 manufacturing facilities, 100 R&D centers, and customers worldwide, covering Asia, Europe, Africa, and the Americas.

Key Questions Addressed by the Health Ingredients Market Report:

What are health ingredients?

What are the key trends driving the health ingredients market?

Who are the major players in the health ingredients market?

How are health ingredients regulated?

What are the health benefits of using health ingredients?

Which segments are prominent in the health ingredients market?

What is the future outlook for the health ingredients market?

How does the health ingredients market vary by region?

Schedule a call with our Analysts to discuss your business needs: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=69194289

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/health-ingredients-market-69194289.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Health Ingredients Market Overview, Size, Share, Growth Drivers, Trends, Opportunities, Key Segments, Leading Players, and Revenue Fotecast – 2027

Diabetes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Diabetes Pipeline Insight 2024” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight’s comprehensive report today! @ Diabetes Pipeline Outlook

 

Key takeaways from the Diabetes Pipeline Report

  • In October 2024:- Novo Nordisk A/S- This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
  • DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
  • The leading Diabetes Companies such as Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.

 

Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs

 

Diabetes Emerging Drugs Profile

 

  • Enavogliflozin – Daewoong

Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

 

  • Golimumab – Janssen Biotech

Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

 

Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight’s detailed report now! @ New Diabetes Drugs

 

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Diabetes Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Diabetes Market Drivers and Barriers

 

Scope of the Diabetes Pipeline Report

  • Coverage- Global
  • Diabetes Companies- Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
  • Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetes: Overview
  4. Causes
  5. Mechanism of Action
  6. Signs and Symptoms
  7. Diagnosis
  8. Disease Management
  9. Pipeline Therapeutics
  10. Comparative Analysis
  11. Therapeutic Assessment
  12. Assessment by Product Type
  13. Assessment by Stage and Product Type
  14. Assessment by Route of Administration
  15. Assessment by Stage and Route of Administration
  16. Assessment by Molecule Type
  17. Assessment by Stage and Molecule Type
  18. Diabetes – DelveInsight’s Analytical Perspective
  19. In-depth Commercial Assessment
  20. Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  21. Diabetes Collaboration Deals
  22. Company-Company Collaborations (Licensing / Partnering) Analysis
  23. Company-University Collaborations (Licensing / Partnering) Analysis
  24. Late Stage Products (Phase III)
  25. Comparative Analysis
  26. Enavogliflozin: Daewoong
  27. Product Description
  28. Research and Development
  29. Product Development Activities
  30. Mid Stage Products (Phase II)
  31. Comparative Analysis
  32. Golimumab: Janssen Biotech
  33. Product Description
  34. Research and Development
  35. Product Development Activities
  36. Drug profiles in the detailed report…..
  37. Early Stage Products (Phase II/I)
  38. Comparative Analysis
  39. IMCY-0098: ImCyse
  40. Product Description
  41. Research and Development
  42. Product Development Activities
  43. Drug profiles in the detailed report…..
  44. Pre-clinical and Discovery Stage Products
  45. Comparative Analysis
  46. ENT-001: Enthera
  47. Product Description
  48. Research and Development
  49. Product Development Activities
  50. Drug profiles in the detailed report…..
  51. Inactive Products
  52. Comparative Analysis
  53. Diabetes Key Companies
  54. Diabetes Key Products
  55. Diabetes- Unmet Needs
  56. Diabetes- Market Drivers and Barriers
  57. Diabetes- Future Perspectives and Conclusion
  58. Diabetes Analyst Views
  59. Diabetes Key Companies
  60. Appendix 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

UAE Dairy Market Size, Share, Trends, Industry Analysis, Report 2024-2032

The market is growing rapidly due to rising demand for dairy products, supported by population growth and increased health awareness.

UAE Dairy Market Overview

Base Year: 2023

Historical Years: 2018-2023

Forecast Years: 2024-2032

Market Growth Rate: 4.50% (2024-2032)

According to the latest report by IMARC Group, the UAE dairy market size is projected to grow at a CAGR of 4.50% from 2024 to 2032. The market is growing rapidly due to rising demand for dairy products, supported by population growth and increased health awareness.

UAE Dairy Market Trends and Drivers:

The rising health consciousness as well as a growing need for diverse dairy products are responsible for the growth of the UAE dairy market. Additionally, the market is propelling as there is an increasing preference for products rich in nutrients such as calcium, protein, and probiotics. This has boosted the consumption of functional dairy products like yogurt, fortified milk, and low-fat options. The expanding expatriate population has also fueled demand for a broader range of dairy products, including specialty cheeses and international dairy brands. Moreover, the rising popularity of convenient, ready-to-consume dairy products, such as flavored milk, dairy snacks, and packaged yogurt, is further propelling the market. 

A significant trend shaping the UAE dairy market is the shift towards plant-based and lactose-free alternatives. In addition to this, dairy manufacturers are diversifying their product lines to include almond, soy, and oat-based alternatives, with a growing number of consumers adopting vegan and lactose-free diets due to health and environmental concerns. The rise of organic and sustainably sourced dairy products is also gaining traction as consumers increasingly prioritize food quality and sustainability. Furthermore, advancements in cold chain logistics and the growth of modern retail and e-commerce platforms have made it simple for consumers to access a wider range of dairy products, from fresh milk to imported specialty items. As the need for healthier and more sustainable food options continues to rise, the UAE dairy market is expected to see sustained growth over the forecasted period, driven by innovation and evolving consumer preferences.

Request for a sample copy of this report: https://www.imarcgroup.com/uae-dairy-market/requestsample

UAE Dairy Market Industry Segmentation:

The report has segmented the market into the following categories:

Product Type Insights:

  • Liquid Milk
  • Flavored Milk
  • Cream
  • Butter
  • Cheese
  • Yoghurt
  • Ice Cream
  • Anhydrous Milk Fat (AMF)
  • Skimmed Milk Powder (SMP)
  • Whole Milk Powder (WMP)
  • Whey Protein
  • Lactose Powder
  • Curd
  • Others

 

Regional Insights:

  • Dubai
  • Abu Dhabi
  • Sharjah
  • Others

 

Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=24528&flag=C

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Key highlights of the Report:

  • Market Performance (2018-2023)
  • Market Outlook (2024-2032)
  • COVID-19 Impact on the Market
  • Porter’s Five Forces Analysis
  • Strategic Recommendations
  • Historical, Current and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

 

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Other Latest Research Reports:

UAE Electric Vehicle Market Size, Share and Forecast 2024-2032

UAE Residential Real Estate Market Size, Share, Trends, Report 2024-2032

UAE E-bike Market Size, Share and Trends 2024-2032

UAE IT Services Market Size, Share and Forecast 2024-2032

UAE Telecom Market Size, Share and Report 2024-2032

 

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1-631-791-1145
Address:134 N 4th St.
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: UAE Dairy Market Size, Share, Trends, Industry Analysis, Report 2024-2032

Soft Drinks Market Size to Worth USD 872.8 Billion by 2032 | With a 4.18% CAGR

“Soft Drinks Market Report 2024-32”

Global Soft Drinks Industry: Key Statistics and Insights in 2024-2032

Summary:

  • The global soft drinks market size reached USD 604.0 Billion in 2023.
  • The market is expected to reach USD 872.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.18% during 2024-2032.
  • North America leads the market, accounting for the largest soft drinks market share.
  • Carbonated holds the largest share in the soft drinks industry.
  • Hypermarkets and supermarkets represent the leading distribution channel segment.
  • Innovation in flavors and ingredients is a primary driver of the soft drinks market.
  • The growing demand for sustainable packaging and the increasing number of e-commerce platforms technologies are reshaping the soft drinks market.

Request PDF Sample for more detailed market insights: https://www.imarcgroup.com/soft-drinks-market/requestsample

Industry Trends and Drivers:

  • Innovation in flavors and ingredients:  

Brands are experimenting with exotic fruits, botanical infusions, and even savory elements to create distinct beverages that stand out in the competitive market. Some companies are blending traditional flavors with modern twists, such as mixing tropical fruits with herbs or spices. Furthermore, the use of natural sweeteners like stevia, monk fruit, and agave is becoming more common, allowing brands to create healthier drinks without compromising on flavor. Additionally, innovations extend to the functional benefits of these beverages, with more products offering enhanced hydration, energy boosts, or relaxation benefits. By continually refreshing their product lines with these innovations, companies are able to maintain consumer interest and expand their market share.

  • Growing demand for sustainable packaging:

Consumers are becoming more aware about the impact of plastic waste on the environment, leading to a preference for eco-friendly packaging options. Beverage companies are responding by adopting recyclable, biodegradable, and reusable packaging materials to align with this shift in user values. Aluminum cans and glass bottles, which are perceived as more sustainable alternatives to plastic, are becoming more widely used. Additionally, brands are exploring innovative materials, such as plant-based plastics, paper bottles, and other biodegradable solutions, to reduce their carbon footprints. Companies are also promoting closed-loop recycling programs and refillable bottle schemes to appeal to environmentally conscious individuals. The focus on sustainability extends beyond packaging, with many manufacturers seeking to lower their overall environmental impact by reducing water usage, energy usage, and waste during production processes.

  • Rise of e-commerce and online beverage sales:

Online shopping is becoming more convenient and popular, which is encouraging individuals to buy beverages online. The convenience of home delivery, along with the availability of a wider range of products online compared to traditional stores, is attracting people to e-commerce platforms. Subscription services offering monthly beverage boxes or customized drink deliveries are also gaining popularity, particularly among younger, tech-savvy individuals. In addition, online platforms enable companies to gather valuable user data, helping brands tailor their products and marketing strategies more effectively. This digital transformation is expanding the reach of soft drink brands, allowing them to cater to a wider audience and drive sales through direct-to-consumer (DTC) channels.

Buy Report: https://www.imarcgroup.com/checkout?id=12627&method=502

Soft Drinks Market Report Segmentation:

Breakup By Product:

  • Carbonated
  • Non-Carbonated

Carbonated exhibits a clear dominance in the market attributed to their widespread preference and strong brand presence worldwide.

Breakup By Distribution Channel:

  • Hypermarkets and Supermarkets
  • Convenience Store
  • Online
  • Others

Hypermarkets and supermarkets represent the largest segment, as they offer a wide variety of soft drinks, competitive pricing, and easy accessibility for consumers.

Breakup By Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America dominates the market due to high consumption rates, advanced retail infrastructure, and the presence of key players.

Top Soft Drinks Market Leaders:

The soft drinks market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

  • Arizona Beverage Company
  • Asahi Group Holdings Ltd.
  • Keurig Dr Pepper Inc.
  • National Beverage Corp.
  • Nestlé S.A.
  • Pepsico Inc.
  • Purity Soft Drinks Ltd.
  • Red Bull GmbH
  • Refresco Group BV
  • The Coca-Cola Company

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Related Reports By IMARC Group:

Liquefied Petroleum Gas Market Size, Share and Research Report 2024-2032

Mining Drilling Services Market Size, Growth and Research Report 2024-2032

Energy as a Service Market Size, Share and Trends Report 2024-2032

Flue Gas Desulfurization Market Size, Share and Growth Report 2024-2032

Wind Turbine Components Market Size, Share and Forecast Report 2024-2032

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1-631-791-1145
Address:134 N 4th St.
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Drinks Market Size to Worth USD 872.8 Billion by 2032 | With a 4.18% CAGR

Hypertrophic Cardiomyopathy Treatment Market Size in the 7MM was ~USD 646 Million in 2023, estimated DelveInsight

Hypertrophic Cardiomyopathy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hypertrophic Cardiomyopathy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Hypertrophic Cardiomyopathy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Hypertrophic Cardiomyopathy Market by downloading the comprehensive report from DelveInsight @ Hypertrophic Cardiomyopathy Treatment Market Size

 

Key Takeaways from the Hypertrophic Cardiomyopathy Market Report

  • As per DelveInsight’s assessments, males are more affected by HCM than females. Also, the cases are projected to increase by 2034 in the United States.
  • As per assessments by DelveInsight analysts, there were nearly 2,887 diagnosed prevalent cases of Obstructive HCM (HOCM), and 1,443 diagnosed prevalent cases of Non-obstructive HCM (HNCM) in 2023 in Japan.
  • In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of HCM in the 7MM was 246,272 in 2023. The highest diagnosed prevalent cases of HCM were accounted by the US for 48% in 2022 which were approximately of the 7MM. These cases are expected to increase during the forecast period (2023–2034).
  • The leading Hypertrophic Cardiomyopathy Companies such as Bristol Myers Squibb, Cytokinetics, Novartis, Imbria Pharmaceuticals, Univar Solutions B.V. and others.
  • Promising Hypertrophic Cardiomyopathy Therapies such as Mavacamten, Sotagliflozin, and others.

 

Gain a competitive edge in the Hypertrophic Cardiomyopathy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Hypertrophic Cardiomyopathy Treatment Drugs

 

Hypertrophic Cardiomyopathy Epidemiology Segmentation in the 7MM

  • Total Prevalent Cases
  • Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Type-specific Diagnosed Prevalent Cases
  • Total Treated Cases

 

Hypertrophic Cardiomyopathy Market Insights

Current pharmacological strategies for hypertrophic cardiomyopathy (HCM) focus on symptom management, particularly for obstructive HCM. Treatment primarily targets left ventricular outflow tract (LVOT) obstruction, using β-adrenergic antagonists, calcium channel blockers, and antiarrhythmic drugs. “CAMZYOS (Mavacamten) is the first and only cardiac myosin inhibitor approved by the US FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.”

 

Discover key developments and opportunities in the Hypertrophic Cardiomyopathy Market. Click here to learn more from DelveInsight’s latest report @ Hypertrophic Cardiomyopathy Market Size

 

Hypertrophic Cardiomyopathy Marketed Drugs

  • Mavacamten: Bristol Myers Squibb

Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance.

 

Hypertrophic Cardiomyopathy Emerging Drugs

  • Aficamten (CK-274): Cytokinetics

Aficamten, or CK-274, is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations for the potential treatment of hypertrophic cardiomyopathies (hypertrophic cardiomyopathy).

 

  • MYK-224: Bristol Myers Squibb

MYK-224 is a small molecule drug that is being developed by MyoKardia, a subsidiary of Bristol-Myers Squibb, to treat diastolic heart failure (HFpEF) and obstructive hypertrophic cardiomyopathy. It is taken orally and targets the heart’s cardiac myosin motor protein to normalize filling and contractility.

 

Hypertrophic Cardiomyopathy Market Outlook

Cardiomyopathy is a term that refers to abnormalities of heart muscle contractility, covering a heterogeneous range of etiologies. Hypertrophic cardiomyopathy is characterized by left ventricular hypertrophy and hypercontractility. It is almost always caused by mutations of genes encoding sarcomeric proteins. Current pharmacological treatment strategies of Hypertrophic cardiomyopathy are mainly centered on managing the symptoms and minimizing disease progression. However, it is important to keep in mind that these strategies are not disease-specific since they target the neurohormonal system and excitation–contraction coupling (ECC) while the basic disease mechanism remains untreated.

 

Download DelveInsight’s Hypertrophic Cardiomyopathy Market report today and stay ahead in this rapidly evolving field. @ Hypertrophic Cardiomyopathy Clinical Trials

 

Scope of the Hypertrophic Cardiomyopathy Market Report

  • Coverage- 7MM
  • Hypertrophic Cardiomyopathy Companies- Bristol Myers Squibb, Cytokinetics, Novartis, Imbria Pharmaceuticals, Univar Solutions B.V. and others.
  • Hypertrophic Cardiomyopathy Therapies- Mavacamten, Sotagliflozin, and others.
  • Hypertrophic Cardiomyopathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Hypertrophic Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Hypertrophic Cardiomyopathy Market Access and Reimbursement

 

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy Market Trends @ Hypertrophic Cardiomyopathy Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Hypertrophic Cardiomyopathy Market Overview at a Glance

4 Epidemiology And Market Forecast Methodology

5 Executive Summary of Hypertrophic Cardiomyopathy

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Products

12 Hypertrophic Cardiomyopathy: Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix

18 Bibliography

19 Report Methodology

20 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertrophic Cardiomyopathy Treatment Market Size in the 7MM was ~USD 646 Million in 2023, estimated DelveInsight

Cyber Weapons Market is Expected to Reach USD 110.6 Billion by 2032 | Grow CAGR by 7.29%

The global cyber weapons market size reached US$ 58.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 110.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.29% during 2024-2032.

Summary: 

  • The global cyber weapons market size reached USD 58.7 Billion in 2023.
  • The market is expected to reach USD 110.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.29% during 2024-2032.
  • North America leads the market, accounting for the largest cyber weapons market share.
  • Defensive accounts for the majority of the market share in the type segment as governments focus on protecting critical infrastructure and preventing cyberattacks to ensure national security. 
  • National defensive system holds the largest share in the cyber weapons industry.
  • The growing utilization of offensive cyber capabilities by nation-states is a primary driver of the cyber weapons market.
  • The surging demand for cyber weapons to safeguard national security is propelling the cyber weapons market.

 

Request Sample For PDF Report: https://www.imarcgroup.com/cyber-weapons-market/requestsample

Industry Trends and Drivers: 

  • Increasing Use of Offensive Cyber Capabilities by Nation-States:

The cyber weapons market is witnessing significant growth as nation-states increasingly invest in offensive cyber capabilities to enhance their geopolitical strategies. Governments around the world are developing and deploying sophisticated cyber weapons to disrupt critical infrastructure, military systems, and financial networks of rival nations. This trend is driven by the growing reliance on digital infrastructure, which makes these systems attractive targets for state-sponsored cyberattacks. Countries are focusing on building advanced cyber arsenals, including malware, ransomware, and other tools that can infiltrate networks and cause widespread disruption without physical confrontation. The rise of cyber warfare as a central element of modern military strategy has pushed national defense agencies to allocate substantial resources to the development and deployment of cyber weapons.

  • Growing Demand for Cyber Weapons to Protect National Security:

As cyber threats evolve, there is a growing demand for cyber weapons to defend against potential attacks on national security. Governments are increasingly concerned about the vulnerability of their critical infrastructure, such as power grids, transportation systems, and communication networks, to cyberattacks. To address this, many countries are expanding their cyber defense capabilities by acquiring offensive and defensive cyber weapons. These tools are designed to counter foreign cyberattacks, mitigate the damage, and retaliate when necessary. The development of cyber defense programs is being prioritized across both developed and emerging nations, with an emphasis on building a robust cyber weaponry arsenal to safeguard national interests in the event of a cyber conflict.

  • Increased Private Sector Involvement in Cyber Weapon Development:

The private sector is playing an increasingly important role in the development of cyber weapons as governments turn to technology companies for expertise in creating advanced cybersecurity tools. Defense contractors and cybersecurity firms are partnering with government agencies to design and deploy cyber weapons capable of both offensive and defensive operations. This collaboration is driven by the need for cutting-edge technology to counter sophisticated cyber threats posed by other nation-states and rogue actors. Private sector companies are contributing innovations in artificial intelligence (AI), machine learning, and encryption technologies that are being integrated into cyber weapon systems. As a result, there is a growing market for commercial companies providing specialized cyber capabilities to government agencies, further driving the expansion of the cyber weapons market.

Buy Now: https://www.imarcgroup.com/checkout?id=11701&method=502

Report Segmentation:

The report has segmented the market into the following categories:

Type Insights:

  • Defensive
  • Offensive

Defensive accounts for the majority of shares as governments prioritize safeguarding critical infrastructure and mitigating cyberattacks to protect national security.

Application Insights:

  • National Defensive System
  • Industrial Control System
  • Communication Network
  • Automated Transportation System
  • Smart Power Grid
  • Others

National defensive system exhibits a clear dominance due to the increasing need for countries to fortify their digital infrastructure against sophisticated cyber threats from foreign adversaries.

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America holds the leading position owing to a large market for cyber weapons driven by significant government investments in cybersecurity and advanced military capabilities, particularly in the United States.

Top Cyber Weapons Market Leaders:

  • Airbus SE
  • BAE Systems plc
  • Cisco Systems Inc.
  • General Dynamics Corporation
  • Kaspersky Lab, Lockheed Martin Corporation
  • Mandiant Inc. (Google LLC)
  • Northrop Grumman Corporation
  • Raytheon Technologies Corporation
  • The Boeing Co.

Related Topics By IMARC Group:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1-631-791-1145
Address:134 N 4th St.
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cyber Weapons Market is Expected to Reach USD 110.6 Billion by 2032 | Grow CAGR by 7.29%

Systemic Mastocytosis Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Systemic Mastocytosis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Systemic Mastocytosis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Systemic Mastocytosis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Systemic Mastocytosis, historical and forecasted epidemiology as well as the Systemic Mastocytosis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Systemic Mastocytosis Market by downloading the comprehensive report from DelveInsight @ Systemic Mastocytosis Treatment Market Size

 

Key Takeaways from the Systemic Mastocytosis Market Report

  • In accordance with Bista Amir et al. (2021), the age-adjusted incidence of Systemic Mastocytosis in the United States is approximately 0.046 cases per 10,000 individuals, underscoring the rarity of this condition within the general population.
  • According to a study conducted by the Spanish Network on Mastocytosis (REMA), the prevalence of systemic mastocytosis in Spain was estimated at approximately 10.6 per 100,000 individuals in the adult population.
  • According to the National Institute for Health and Care Excellence, an article discussing Systemic Mastocytosis indicates that the estimated prevalence of this condition in England is approximately 1 in every 150,000 individuals. This statistic highlights the rarity of Systemic Mastocytosis within the general population, underscoring the need for heightened awareness and understanding of the disease among healthcare professionals.
  • The leading Systemic Mastocytosis Companies such as AB Science, Blueprint Medicine Corporation, and others.
  • Promising Systemic Mastocytosis Therapies such as Masitinib, Elenestinib, and others.

 

Gain a competitive edge in the Systemic Mastocytosis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Systemic Mastocytosis Treatment Drugs

 

Systemic Mastocytosis Epidemiology Segmentation in the 7MM

  • Total Systemic Mastocytosis Prevalent Cases
  • Total Systemic Mastocytosis Diagnosed Cases
  • Systemic Mastocytosis Gender-specific Diagnosed prevalent cases
  • Systemic Mastocytosis Age-specific Diagnosed prevalent cases  
  • Systemic Mastocytosis Treated Cases

 

Systemic Mastocytosis Market Insights

Systemic Mastocytosis is a condition characterized by the abnormal accumulation of mast cells in various tissues, most commonly affecting the skin, bone marrow, and gastrointestinal tract. The selection of therapy for systemic mastocytosis is influenced by factors such as the patient’s age, gender, and the specific manifestations of the disease. There is no one-size-fits-all treatment approach, as different patients may respond differently based on their individual symptoms and disease severity. Management typically involves a combination of symptom control and, in some cases, targeted therapies aimed at addressing the underlying mast cell proliferation.

 

Discover key developments and opportunities in the Systemic Mastocytosis Market. Click here to learn more from DelveInsight’s latest report @ Systemic Mastocytosis Market Size

 

Systemic Mastocytosis Treatment Landscape

Common treatment options include antihistamines to alleviate symptoms like itching and flushing, corticosteroids for inflammation, and advanced therapies such as tyrosine kinase inhibitors for more aggressive forms of the disease. While many patients can achieve significant symptom relief and improved quality of life through appropriate management, complete remission may be challenging to attain for some. Stratifying systemic mastocytosis according to established clinical guidelines, such as those from the NCCN, is crucial for enhancing management strategies. This approach offers a clinically relevant framework for classifying the disease into specific subtypes, including indolent systemic mastocytosis, smoldering systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

 

Systemic Mastocytosis Emerging Therapies Assessment

  • Elenestinib (BLU-263): Blueprint Medicines Corporation
  • Bezuclastinib (CGT9486): Cogent Biosciences, Inc.

 

Download DelveInsight’s Systemic Mastocytosis Market report today and stay ahead in this rapidly evolving field. @ Systemic Mastocytosis Clinical Trials

 

Scope of the Systemic Mastocytosis Market Report

  • Coverage- 7MM
  • Systemic Mastocytosis Companies- AB Science, Blueprint Medicine Corporation, and others.
  • Systemic Mastocytosis Therapies- Masitinib, Elenestinib, and others.
  • Systemic Mastocytosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Systemic Mastocytosis Unmet Needs, KOL’s views, Analyst’s views, Systemic Mastocytosis Market Access and Reimbursement

 

Download the report to understand which factors are driving Systemic Mastocytosis Market Trends @ Systemic Mastocytosis Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Systemic Mastocytosis

3. Competitive Intelligence Analysis for Systemic Mastocytosis

4. Systemic Mastocytosis: Market Overview at a Glance

5. Systemic Mastocytosis: Disease Background and Overview

6. Patient Journey

7. Systemic Mastocytosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Mastocytosis Unmet Needs

10. Key Endpoints of Systemic Mastocytosis Treatment

11. Systemic Mastocytosis Marketed Products

12. Systemic Mastocytosis Emerging Therapies

13. Systemic Mastocytosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Systemic Mastocytosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Mastocytosis Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight